77395-10-9

Basic information

• Product Name: 5-BROMO-7-METHYL-1H-INDOLE-2,3-DIONE
• Synonyms: TIMTEC-BB SBB002521;BUTTPARK 76\07-22;AURORA 18112;5-BROMO-7-METHYL-1H-INDOLE-2,3-DIONE;5-BROMO-7-METHYLISATIN;1H-indole-2,3-dione, 5-bromo-7-methyl-;7-Methyl-5-broMoisatin;5-BroMo-7-Methylindoline-2,3-dione
• CAS NO: 77395-10-9
• Molecular Formula: C₉H₆BrNO₂
• Molecular Weight: 240.05
• Product Categories: Indane/Indanone and Derivatives
• Mol File: 77395-10-9.mol
• Article Data: 6

Chemical Properties

• Melting Point: 262℃ (decomposition)
• Appearance: /
• Density: 1.714 g/cm³
• Storage Temp.: -20°C Freezer, Under inert atmosphere
• Solubility: DMSO (Slightly), Methanol (Slightly)
• CAS DataBase Reference: 5-BROMO-7-METHYL-1H-INDOLE-2,3-DIONE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-BROMO-7-METHYL-1H-INDOLE-2,3-DIONE(77395-10-9)
• EPA Substance Registry System: 5-BROMO-7-METHYL-1H-INDOLE-2,3-DIONE(77395-10-9)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• HazardClass: IRRITANT
• Hazardous Substances Data: 77395-10-9(Hazardous Substances Data)

Usage

Uses

5-Bromo-7-methyl-1H-indole-2,3-dione can be used as an anti-inflammatory agent. It can also be used to modulate CFTR activity and AMPA receptor modules.

Upstream product

• 583-75-5 4-Bromo-2-methylaniline 
• 1189051-96-4 3-methyl-2-nitro-1-[2-(trimethylsilyl)ethynyl]-benzene 
• 95-53-4 o-toluidine 
• 1127-59-9 7-methyl-1H-indole-2,3-dione 

Downstream Products

• 206548-13-2 2-amino-5-bromo-3-methylbenzoic acid 
• 908597-10-4 2,5-dibromo-3-methyl benzoic acid methyl ester 
• 908597-09-1 2,5-dibromo-3-methylbenzoic acid 
• 2036075-04-2 7-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indolin-2-one 

Relevant articles and documents

A reassessment of mycophenolic acid as a lead compound for the development of inhibitors of chikungunya virus replication

Mycophenolic acid (MPA) has been previously reported as an inhibitor of the chikugunya virus (CHIKV) with an EC50 value of 0.2 μM. We used MPA as a lead compound designing and synthesizing a series of isatins and benzolactones in a typical medicinal chemistry program. The synthesis and testing of 19 derivatives produced compounds with no desired activity which prompted us to retest the lead compound, MPA. We can reveal that MPA shows no anti-CHIKV activity and therefore needs to be reassessed as a lead compound for this target.

QUINAZOLINES AND AZAQUINAZOLINES AS DUAL INHIBITORS OF RAS/RAF/MEK/ERK AND PI3K/AKT/PTEN/MTOR PATHWAYS

The present application provides novel quinazolines and azaquinazolines and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful in for co-regulating RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways by administering a therapeutically effective amount of one or more of the compounds of formula (I), wherein X, Y, T and R4, and R6 to R8' are defined herein, to a patient. By doing so, these compounds are effective in treating conditions associated with the dysregulation of the RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways. A variety of conditions can be treated using these compounds and include diseases which are characterized by abnormal cellular proliferation. In one embodiment/ the disease is cancer.

Synthesis and biological evaluation of quinoline salicylic acids as P-selectin antagonists

Leukocyte recruitment of sites of inflammation and tissue injury involves leukocyte rolling along the endothelial wall, followed by firm adherence of the leukocyte, and finally transmigration of the leukocyte across cell junctions into the underlying tissue. The initial rolling step is mediated by the interaction of leukocyte glycoproteins containing active moieties such as sialyl Lewisx (sLex) with P-selectin expressed on endothelial cells. Consequently, inhibition of this interaction by means of a small molecule P-selectin antagonist is an attractive strategy for the treatment of inflammatory diseases such as arthritis. High-throughput screening of the Wyeth chemical library identified the quinoline salicylic acid class of compounds (1) as antagonists of P-selectin, with potency in in vitro and cell-based assays far superior to that of sLex. Through iterative medicinal chemistry, we identified analogues with improved P-selectin activity, decreased inhibition of dihydrooratate dehydrogenase, and acceptable CYP profiles. Lead compound 36 was efficacious in the rat AIA model of rheumatoid arthritis.